J Endod:氯膦酸盐和依替膦酸盐与次氯酸钠的混合物溶解有机组织的比较

2019-12-22 lishiting MedSci原创

氯膦酸盐和次氯酸钠(NaOCl)混合比依替膦酸盐和次氯酸盐混合能够更好的释放游离有效氯(FAC)。这篇研究的目的是为了比较氯膦酸盐和依替膦酸盐混合物的有机组织溶解以及FAC释放情况。

氯膦酸盐和次氯酸钠(NaOCl)混合比依替膦酸盐和次氯酸盐混合能够更好的释放游离有效氯(FAC)。这篇研究的目的是为了比较氯膦酸盐和依替膦酸盐混合物的有机组织溶解以及FAC释放情况。研究取猪的上颌粘膜组织作为样本,分别加入到32°C的下列刚混合的溶剂中:0.26 mol/L的氯膦酸盐和5% NaOCl (0.26 mol/L-5% NaOCl), 0.26 mol/L依替膦酸盐-5% NaOCl, 5% NaOCl, 0.26 mol/L氯膦酸盐, 0.26 mol/L依替膦酸盐或PBS溶液。混入后,记录最初的以及15分钟时组织的重量和FAC。FAC通过碘滴定计算。第二步,混合6小时后,粘膜加入0.26 mol/L氯膦酸盐-2.5% NaOCl, 2.5% NaOCl, 0.52 mol/L氯膦酸盐-5% NaOCl, 5% NaOCl或PBS溶液。在0, 5, 10和15分钟记录样本的重量。采用Analysis of variance对数据进行统计学分析(α < .05)。结果显示,即刻混合后,0.26 mol/L氯膦酸盐-5% NaOCl与5% NaOCl对组织的溶解程度相似

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1529320, encodeId=0f1e152932061, content=<a href='/topic/show?id=cf226303999' target=_blank style='color:#2F92EE;'>#次氯酸钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63039, encryptionId=cf226303999, topicName=次氯酸钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbb11925025, createdName=millore, createdTime=Tue Dec 24 12:16:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377350, encodeId=0b343e735033, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 24 05:03:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377317, encodeId=ee8c3e731739, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Dec 23 06:24:00 CST 2019, time=2019-12-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1529320, encodeId=0f1e152932061, content=<a href='/topic/show?id=cf226303999' target=_blank style='color:#2F92EE;'>#次氯酸钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63039, encryptionId=cf226303999, topicName=次氯酸钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbb11925025, createdName=millore, createdTime=Tue Dec 24 12:16:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377350, encodeId=0b343e735033, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 24 05:03:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377317, encodeId=ee8c3e731739, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Dec 23 06:24:00 CST 2019, time=2019-12-23, status=1, ipAttribution=)]
    2019-12-24 thm112988

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1529320, encodeId=0f1e152932061, content=<a href='/topic/show?id=cf226303999' target=_blank style='color:#2F92EE;'>#次氯酸钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63039, encryptionId=cf226303999, topicName=次氯酸钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbb11925025, createdName=millore, createdTime=Tue Dec 24 12:16:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377350, encodeId=0b343e735033, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 24 05:03:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377317, encodeId=ee8c3e731739, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Dec 23 06:24:00 CST 2019, time=2019-12-23, status=1, ipAttribution=)]